Coagulation Activation Markers and Pre Eclampsia : Correlation With Complications
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pre Eclampsia
- Sponsor
- University Hospital, Lille
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Endogenous thrombin potential
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The primary purpose of the trial is to evaluate coagulation activator markers in patients with pre eclampsia compared to control (normal pregnancy) and to correlate these markers with the severity of the pathology.
Detailed Description
100 pre-eclamptic patients will be compared to 200 control patients (100 control matched on gestational age at inclusion and 100 control matched on delivery mode (section). Blood and urine samples will be collected at PE diagnosis, delivery and post partum. Two axes will be considered: 1. Thrombography, or kinetic measurement of thrombin generation, by studying the coagulant profile according to Hemker's method in CAT System (Calibrated Automated Thrombogram) and by thromboelastogram in ROTEM technique (delocalized coagulation analyzer), in parallel to specific activation markers (thrombin-antithrombin complex, fibrin monomers). 2. The balance of prostacyclin/thromboxane A2 by using ELISA method for urine samples and genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase's promoter CYP8A1).
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years old
- •diagnosis of pre eclampsia
Exclusion Criteria
- •multiple pregnancy
- •less than 18 year old
Outcomes
Primary Outcomes
Endogenous thrombin potential
Time Frame: at preeclampsia diagnosis
comparison of Endogenous thrombin potential between patients with Preclampsia (PE) (at the moment of the diagnosis of PE) compared to control (at the same gestational age)
Secondary Outcomes
- In preeclampsia group : correlation between biological markers and severity of the disease(at the diagnosis of preeclampsia)
- evolution of endogenous thrombin potential in women with preeclampsia(between the diagnosis of preeclampsia and day 2 of the post partum period)
- genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase promoter CYP8A1(at pre eclampsia diagnosis)